Previous meta-analyses demonstrated an interaction between obesity and superior survival outcomes of patients with mRCC, the majority of whom received vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs) [2], [3]. The gene discussed is VEGFA; the disease is obesity due to melanocortin 4 receptor deficiency.